Simcere Pharmaceutical Group (HKSE:02096) Debt-to-Equity : 0.20 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Debt-to-Equity?

Simcere Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,198 Mil. Simcere Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$366 Mil. Simcere Pharmaceutical Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$7,900 Mil. Simcere Pharmaceutical Group's debt to equity for the quarter that ended in Dec. 2023 was 0.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Simcere Pharmaceutical Group's Debt-to-Equity or its related term are showing as below:

HKSE:02096' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.2 Med: 0.62 Max: 1.99
Current: 0.2

During the past 7 years, the highest Debt-to-Equity Ratio of Simcere Pharmaceutical Group was 1.99. The lowest was 0.20. And the median was 0.62.

HKSE:02096's Debt-to-Equity is ranked better than
59.91% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HKSE:02096: 0.20

Simcere Pharmaceutical Group Debt-to-Equity Historical Data

The historical data trend for Simcere Pharmaceutical Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Debt-to-Equity Chart

Simcere Pharmaceutical Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.99

0.62

0.25

0.21

0.20

Simcere Pharmaceutical Group Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial							0.25	0.25	0.21	0.13	0.20

Competitive Comparison of Simcere Pharmaceutical Group's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Simcere Pharmaceutical Group's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's Debt-to-Equity falls into.

Simcere Pharmaceutical Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Simcere Pharmaceutical Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1197.667	+	365.588)	/	7900.076
	=	0.20

Simcere Pharmaceutical Group's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1197.667	+	365.588)	/	7900.076
	=	0.20

Simcere Pharmaceutical Group (HKSE:02096) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Simcere Pharmaceutical Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group (HKSE:02096) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Debt-to-Equity

Traded in Other Exchanges

S2P:Germany

Address

No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042

Website

https://www.simcere.com

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Executives

Wang Xi	2305 Beneficiary of a trust
Ren Jinsheng	2202 Interest of your spouse
Right Wealth Holdings Limited	2501 Other
Wang Xi	2501 Other
Simcere Investments Group Limited	2501 Other
Excel Investments Group Limited	2501 Other
Simcere Pharmaceutical Holding Limited	2501 Other
Simcere Holding Limited	2501 Other
Artking Global Limited	2501 Other
Ren Zhen	2501 Other
Ren Yong	2501 Other
Ren Weidong	2501 Other
Peng Suqin	2501 Other
P&h Holdings Group Ltd.	2501 Other
Li Shimeng	2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines